Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

Table 2

Tumor response evaluation based on the WHO and RECIST criteria (stage 1: 15 patients; stage 2: 10 patients).

Response evaluation	Stage 1		Stage 2
	Cycle 2 (N = 15)	Cycle 4 (N = 8)	Cycle 2 (N = 10)	Cycle 4 (N = 5)
WHO
Partial response	1	0	0	0
Stable disease	7	1	5	2
Progressive disease	5	5	4	3
Others	2	2	1	0
RECIST
Partial response	0	0	0	0
Stable disease	9	2	5	4
Progressive disease	4	4	4	1
Others	2	2	1	0

Partial response was unconfirmed and thus not counted as clinical benefit.